Drug Profile
Research programme: CD26 antigen antagonists - Abbott Laboratories
Alternative Names: A 916165; ABT 341; Dipeptidyl peptidase IV antagonists - Abbott LaboratoriesLatest Information Update: 25 Jan 2013
Price :
$50
*
At a glance
- Originator Abbott Laboratories
- Class Small molecules; Triazoles
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 18 Dec 2006 A study has been added to the pharmacokinetics section
- 22 Sep 2006 Data presented at the 232nd American Chemical Society National Meeting (232nd-ACS-2006) have been added to the pharmacokinetics section
- 06 Jun 2006 Preclinical trials in Type-2 diabetes mellitus in USA (unspecified route)